Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues

Journal of Clinical Immunology

Volumn 20, Issue 2, 2000, Pages 85-93

  Livingston, Philip O ^a,b   Ragupathi, Govindaswami ^a   Musselli, Cristina ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b A Subsidiary of Lantheus Holdings   (United States)

Author keywords

Antigens; B cells

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; BCG VACCINE; CANCER ANTIBODY; CANCER VACCINE; CARBOHYDRATE ANTIGEN; CD20 ANTIGEN; EDRECOLOMAB; GANGLIOSIDE ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; MUCIN; PACLITAXEL; TRASTUZUMAB; TUMOR ANTIGEN;

ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BLOOD BRAIN BARRIER; CANCER CELL; CANCER RECURRENCE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, NEOPLASM; AUTOANTIBODIES; AUTOANTIGENS; CANCER VACCINES; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 0034067596     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006697728855     Document Type: Article

References (66)

1. 1. Sahin U, Tureci O, Pfreundschuh M: Serological identification of human tumor antigens. Curr Opin Immunol 9:709-16, 1997
2. 2. Dighiero G, Lymberi P, Guilbert B, Ternynck T, Ayrameas S: Natural autoantibodies constitute a substantial part of normal circulating immunoglobulins. Ann N Y Acad Sci Autoimmunity 475:135-145, 1986
3. 3. Allison AC: Autoimmune diseases: Concepts of pathogenesis and control. Autoimmunity 4:91-139, 1977
4. 4. Roitt I, Brostoff J, Male D: Autoimmunity and autoimmune disease. Immunology 28:367-377, 1998
5. 5. Anhalt GJ, Kim SC, Stanley JR: Paraneoplastic pemphigus: An autoimmune microcutaneous disease associated with neoplasia. N Engl J Med 323:1729-1735, 1990
6. 6. Dalmau JO, Posner JB: Neurological paraneoplastic syndromes. Prog Clin Neurosci 4:443-453, 1998
7. 7. Dalmau J, Gultekin HS, Posner JB: Paraneoplastic neurologic syndromes: Pathogenesis and physiopathology. Brain Pathol 9:275-284, 1999
8. 8. Benyahia B, Liblau R, Merle-Beral H, Tourani JM, Dalmau J, Delattre, JY: Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neural 45:162-167, 1999
9. 9. Graus F, Dalmau J, Rene R, Tora M, Malats N, Verschuuren JJ, Cardenal F, Vinolas N, Garcia de Muro J, Vadell C, Mason WP, Rosell R, Posner JB, Real FX: Anti-Hu antibodies in patients with small cell lung cancer: Association with complete response to therapy and improved survival. J Clin Oncol 15:2866-2872, 1997
10. 10. Tora M, Graus F, Bolos C, Real FX: Cell surface expression of paraneoplastic encephalomyelitis/sensory neuronopathy-associated Hu antigens in small-cell lung cancers and neuroblastomas. Neurology 48:735-741, 1997
11. 11. Livingston PO: The case for melanoma vaccines that induce antibodies. In Molecular Diagnosis. Prevention and Treatment of Melanoma, JM Kirkwood (ed.) New York, Marcel Dekker 1998, pp 139-157
12. 12. Livingston PO, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Helling F, Ritter G, Oettgen HF, Old LJ: Improved survival in AJCC stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994
13. 13. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF: Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 66:249-254, 1981
14. 14. Winter SF, Sekido Y, Minna JD, McIntire D, Johnson BE, Gazdar AF, Carbone DP: Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: Association with improved survival. J Natl Cancer Inst 85:2012-2018, 1993
15. 15. Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, Lloyd KW, Livingston PO: Selection of carbohydrate tumor antigens as targets for immune attack using immunohistochemistry. I. Focus on gangliosides. Int J Cancer 73:42-49, 1997
16. 16. Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO, Livingston PO: Selection of tumor antigens as targets for immune attack using immunohistochemistry. II. Blood group-related antigens. Int J Cancer 73:50-56, 1997
17. 17. Zhang S, Zhang HS. Reuter VE, Lloyd KO, Scher H, Livingston PO: Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 4:295-302, 1998
18. 18. Zhang S, Zhang HS, Cordon-Cardo C. Ragupathi G, Livingston PO: Selection of tumor antigens as targets for immune attack using immimohistochemistry: III Protein antigens. Clin Cancer Res 4:2669-2676, 1998
19. 19. Hamilton WB, Helling F, Lloyd KO, Livingston PO: Ganglioside expression on human malignant melanoma assessed by quantitative immune thin layer chromatography. Int J Cancer 53:566-573, 1993
20. 20. Davidson NE, Gelmann EP, Lippman ME, Dickson RB: Epidermal growth factor gene expression in estrogen-positive and negative human breast cancer cell lines. Mol Endocrinol 1:216-223, 1987
21. 21. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM: Differential responses of human tumor cell lines to anti-p185 HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255-263, 1993
22. 22. Livingston PO, Ragupathi G: Carbohydrate vaccines that induce antibodies against cancer. Part II. Previous experience and future plans. Cancer Immunol Immunother 45:10-19, 1997
23. 23. Hamilton WB, Helling F, Livingston PO: Ganglioside expression on sarcoma and small-cell lung carcinoma compared to tumors of neuroectodermal origin. Proc AACR 34:491, 1993
24. 24. Helling F, Livingston PO: Ganglioside conjugate vaccines. In: Molecular and Chemical Neuropathology, vol. 21, New York, Humana Press 1994, pp 299-309
25. 25. Gendler, SJ: Molecular cloning and expression of human tumor associated polymorphic epithelial mucin. J Biol Chem 265:15286-15293, 1990
26. 26. Carrato C, Balague C, De Bolos C, Gonzalez E, Gambus G, Planas J. Perini JM, Andreau D: Differential apomucin expression in normal and neoplastic human gastrointestinal tissues. Gastroenterology 107:160-172, 1994
27. 3 ganglioside with CD45RO in resting and activated human T lymphocytes. Cell Immunol 173:131-148, 1996
28. 28. Singhal AK, Fohn M, Hakomori S: Induction of Tn (a-N-acetylgalactosamine-O-serine/threoninine) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res 50:4308-4314, 1990
29. 29. Zhang S, Walberg LA, Ogata S, Itzkowitz SH, Koganty RR, Reddish M, Gandhi SS, Longenecker BM, Lloyd KO, Livingston PO: Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res 55:3364-3368, 1995
30. 30. Taylor-Papdimitriou J, Peterson JA, Arklie J, Burchell J, Ceriani R, Bodmer WF: Monoclonal antibodies to epithelium specific components of the milk fat globule membrane: Production and reactions with cells in culture. Int J Cancer 28:17-21, 1981
31. 31. Scheinberg DA, Chapman PB: Therapeutic applications of monoclonal antibodies for human disease. In Monoclonal Antibodies. Principles and Applications, vol. 2, JR Birch, ES Lennox (eds). New York, John Wiley and Sons, 1995, pp 45-105
32. 32. Schlom J: Monoclonal antibodies in cancer therapy. In Biologic Therapy of Cancer (2nd ed). Philadelphia, PA, J. B. Lippincott Co. 1995, pp 507-521
33. 33. Jurcic JC, Scheinberg DA, Houghton AN: Monoclonal antibody therapy of cancer. In Cancer chemotherapy and Biological Response Modifiers, HM Pinedo, DL Longo, BA Chabner (eds): Amsterdam, Elsevier Science Publishers Annual 17, 1997, 1998, pp 195-216
34. 34. Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Baselga J. Norton J: Addition of herceptin (humanized anti HER2 antibody) to first line chemotherapy for HER2 overexpressing metastalic breast cancer (HER2+/MBC) markedly increases anticancer activicty: A randomized multinational controlled phase III trial. Proceedings of ASCO 17:377, 1998
35. 35. Mendelsohn J, Baselga J: Antibodies to growth factors and receptors. In Biologic Therapy of Cancer (2nd ed) 1995, pp 607-623
36. 36. Cheung N-K V, Lazarus H, Miraldi FD, Abramowsky CR, Kallie S, Saarinen UM, Spitzer T, Strandjord SE, Cocci PF, Berger NA: Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5:1430-1440, 1987
37. 37. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J, the German Cancer Aid 17-1A Study Group: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343: 1177-1183, 1994
38. 38. Leget GA, Czuezman MS: Use of Rituximab, the new FDA-approved antibody. Curr Opin Oncol 10(6):548-551, 1998
39. 39. Lundin J, Osterborg A, Brittinger G, Crowther D, Dombret H, Engert A, Epenetos A, Gisselbrecht C, Huhn D, Jaeger U, Thomas J, Marcus R, Nissen N, Poynton C, Rankin E, Stahel R, Uppen kamp M, Willemze R, Mellstedt H: Campath-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study. European study group of campath-1H treatment in low grade non-Hodgkin's lymphoma. J Clin Oncol 16:3257-3263, 1998
40. 40. Jurcic JO, Caron PC, DeBlasio A, Dumont L, Warrell RP, Scheinberg DA: Targeted therapy with humanized anti-CD33 monoclonal antibody (HuM195) reduces residual disease in acute promyclocytic leukemia. Blood 86:517a, 1995
41. 41. Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, Unst M, Miller DM, Lawson S, Dixon P, Russell CH, LoBuglio AF: Phase I trial of the murine monoclonal anti-GD2 antibody 14G9a in metaslatic melanoma. Cancer Res 52:4342-4347, 1992
42. 42. Mordoh J, Silva C, Albarellos M, Bravo AI, Kairiyama C: Phase I clinical trial in cancer patients of a new monoclonal antibody FC-2.15 reacting with tumor proliferating cells. J Immunother 17:151-180, 1995
43. 43. Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, Slichenmyer W. Randomized phase II study of BR96-Doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 17:478-484, 1999
44. 44. Kuan CT, Pai LH, Pastan L: Immunotoxins containing Pseudomonas exotoxin that target Le Y damage human endothelial cells in an antibody-specific mode: Relevance to vascular leak syndrome. Clin Cancer Res H(12):1589-1594, 1995
45. 45. Tai T, Cahan ID, Tsuchida T, Saxton RE, Irie RF, Morton DL: Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 35:607-612, 1985
46. 46. Livingston PO, Jones M, DeLeo AB, Oettgen HF, Old LJ: Scrological response in stage II melanoma patients receiving allogeneic melanoma cell vaccines. Cancer 56:2194-2200, 1985
47. 47. Livingston PO, Watanoabe T, Shiku H, Houghton AN, Albino A, Takahashi T, Resnick A, Michitsch R, Pinsky CM, Oettgen HF, Old LJ: Serological response of melanoma patients receiving melanoma cell vaccines, I. Autologous cultured melanoma cells. Int J Cancer 30:413-422, 1982
48. 48. Livingston PO, Ritter G, Srivastava P, Padavan M, Calves MJ, Oettegen HF, Old LJ: Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 49:7045-7050, 1989
49. 49. Helling F, Shang Y, Calves M, Oettgen HF, Livingston PO: Increased immunogenicity of GD3 conjugate vaccines: Comparison of various carrier proteins and selection of GD3-KLH for further testing. Cancer Res 54:197-203, 1994
50. 50. Helling F, Shang A, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Oettgen HF, Livingston PO: GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55:2783-2788, 1995
51. 51. Livingston PO, Adluri S, Helling F, Yao T-J, Kensil CR, Newman MJ, Marciani D: Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-KLH conjugate vaccine in patients with malignant melanoma. Vaccine 12:1275-1280, 1994
52. 52. Zhang H, Zhang S, Cheung NK, Ragupathi G, Livingston PO: Antibodies can eradicate cancer micrometastases. Cancer Res 58:2844-2849, 1998
53. 53. Fung PYS, Madej M, Koganty RR, Longenecker BM: Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 50:4308-4314, 1990
54. 54. Dickler MN, Ragupathi G, Liu NX, Musselli C, Martino DJ, Miller VA, Kris MG, Brezicka FT, Livingston PO, Grant SC: Immunogenicity of the fucosyl-GM1-keyhole limpet hemocyanin (KLH) conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res 5:2773-2779, 1999.
55. 55. Maclean GD, Bowen-Yacyshjn MB, Samuel J, Meikle A, Stuart G, Nation J, Poppema S, Jerry M, Koganty R, Wong T, Longenecker BM: Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J Immunother 11:292-305, 1992
56. 56. Adluri S, Helling F, Calves MJ, Lloyd KO, Livingston PO: Immunogenicity of synthetic TF-and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol Immunother 41: 185-192, 1995
57. 57. MacLean GD, Reddish M, Koganty R, Wong T, Gandhi S, Smolenski M, Samuel J, Nabholtz JM, Longenecker BM: Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 36:215-222, 1993
58. 58. Ragupathi G, Slovin S, Adluri S, Sames D, Kim I-J, Kim HM, Spassova M, Bommann WG, Lloyd K, Scher HI, Livingston PO, Danishefsky SJ: A fully synthetic globo H carbohydrate vaccine induces a focused humoral response in prostate cancer patients: A proof of principle. Angewandte. Chemie 38:563-566, 1999
59. 59. Slovin SF, Ragupathi G, Adluri S, Ungers G, Terry K, Kim S, Spassova M, Bornmann WG, Fazzari M, Dantis L, Olkiewicz K, Lloyd KO, Livingston PO, Danishefsky SJ, Scher HI: Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci USA 96:5710-5715, 1999
60. 60. Livingston PO: Approaches to augmenting the immunogenicity of melanoma gangliosides. In From whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 145:147-166, 1995
61. 61. Gilewski T, Adluri S, Zhang S, Ragupathi G, Houghton A, Norton L, Livingston PO: Vaccination of high risk breast cancer patients with Mucin-1 keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res, in press
62. 62. Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO: Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer 85:659-666, 2000.
63. 63. Itzkowitz S, Bloom EJ, Kokal WA, Modin G, Hakamori SI, Kim YS: Sialosyl Tn: a novel mucin antigen associated with prognosis in colorectal carcinoma patients. Cancer 66:1960-1966, 1990
64. 64. MacLean GD, Reddish MA, Koganty RR, Longenecker BM: Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic sTn vaccine. J Immunol 9:59-68, 1996
65. 65. Rosenberg SA: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281-287, 1999
66. 66. DiFronzo LA, Morton DL: Melanoma vaccines: Overview of current status of clinical trials. Adv Oncol in press